Cytek Biosciences, Inc.
CTKB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $848 | $1,234 | $1,373 | $2,183 |
| - Cash | $99 | $167 | $297 | $365 |
| + Debt | $17 | $14 | $18 | $0 |
| Enterprise Value | $766 | $1,081 | $1,095 | $1,818 |
| Revenue | $200 | $193 | $164 | $128 |
| % Growth | 3.9% | 17.7% | 28.2% | – |
| Gross Profit | $111 | $109 | $101 | $79 |
| % Margin | 55.4% | 56.7% | 61.6% | 61.9% |
| EBITDA | -$10 | -$4 | $9 | $9 |
| % Margin | -5% | -2.3% | 5.8% | 7% |
| Net Income | -$6 | -$12 | $3 | $3 |
| % Margin | -3% | -6.3% | 1.6% | 2.3% |
| EPS Diluted | -0.046 | -0.09 | 0.019 | 0.033 |
| % Growth | 48.7% | -582.8% | -43.6% | – |
| Operating Cash Flow | $25 | $5 | -$12 | $5 |
| Capital Expenditures | -$4 | -$5 | -$10 | -$4 |
| Free Cash Flow | $22 | $0 | -$22 | $0 |